

In the claims:

1. (Currently amended) A An isolated, stable glutamic acid decarboxylase (GAD)-peptide-specific Class II *MHC* complex which comprises a recombinant peptide chain comprising (1) the extracellular portion of the  $\beta$  chain of a Class II *MHC* molecule selected from the group consisting of I-Ag7 and DQ, and (2) a GAD peptide selected from the group consisting of SEQ ID NOS:1-13.
2. (Previously presented) The complex of claim 1 wherein said complex further comprises the extracellular portion of the  $\alpha$  chain of said Class II *MHC* molecule.
3. (Previously presented) The complex of claim 1, wherein said Class II *MHC*  $\beta$  chain lacks a complete transmembrane region.
4. (Previously presented) The complex of claim 2, wherein said Class II *MHC*  $\beta$  chain and said Class II *MHC*  $\alpha$  chain lack complete transmembrane regions.
- 5-10. (Canceled).
11. (Previously presented) The complex of claim 1, wherein said GAD peptide is SEQ ID NO: 1.
12. (Previously presented) The complex of claim 1, wherein said GAD peptide is SEQ ID NO: 2.

13. (Previously presented) The complex of claim 1 which further comprises a biotinylation site.

14. (Previously presented) The complex of claim 1 which further comprises an oligohistidine sequence.

15. (Previously presented) The complex of claim 2 which further comprises a biotinylation site.

16. (Previously presented) The complex of claim 2 which further comprises an oligohistidine sequence.

17-22. (Canceled).

23. (Currently amended) A An isolated, stable glutamic acid decarboxylase (GAD)-peptide-specific Class II *MHC* complex which comprises (1) the extracellular portion of a  $\beta$  chain of a Class II *MHC* molecule selected from the group consisting of I-Ag7 and DQ, (2) the extracellular portion of an  $\alpha$  chain of said Class II *MHC* molecule, and (3) a GAD peptide selected from the group consisting of SEQ ID NOS:1-13.

24. (Previously presented) The complex of claim 23 which further comprises a biotinylation site.

25. (Previously presented) The complex of claim 23 which further comprises an oligohistidine sequence.

26-31. (Canceled).

32. (Previously presented) The complex of claim 24 which further comprises a biotin covalently linked to said biotinylation site.

33. (Previously presented) The complex of claim 32 which further comprises an effector-avidin bound to said biotin.

34. (Previously presented) The complex of claim 33, wherein said effector is selected from a label and a toxin.

35-52. (Canceled).

53. (Previously presented) The complex of claim 1 which is a tetrameric complex.

54. (Previously presented) The complex of claim 23 which is a tetrameric complex.